Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13762005 | 0.89 | CYP4F2 (0.36) | CYP4F2CYP4A11PKMMEN1KMT2A | |
| SCHEMBL10136659 | 0.88 | CYP4F2 (0.33) | CYP4F2CYP4A11PKMKDM4EMAPK1 | |
| SCHEMBL1361264 | 0.85 | CYP4F2 (0.44) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL16150101 | 0.82 | CYP4F2 (0.50) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL10023943 | 0.82 | CYP4F2 (0.50) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL12667953 | 0.82 | CYP4F2 (0.46) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL12963166 | 0.81 | CYP4F2 (0.37) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL23132525 | 0.77 | CYP4F2 (0.42) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL6910898 | 0.77 | CYP4F2 (0.39) | CYP4F2CYP4A11PKMKDM4EMEN1 | |
| SCHEMBL8205942 | 0.77 | CYP4F2 (0.44) | CYP4F2CYP4A11PKMKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309737-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110009621-A1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | Raap Polymere GmbH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20090203860-A1 | Nonpolar phase-soluble methathesis catalysts | NATIONAL SCIENCE FOUNDATION | 2009-08-13 | — | — | US | disclosed |
| EP-2027920-A1 | Catalysts for metathesis reactions | Lanxess Deutschland GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009621-A1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | SCO2, SOD1, PPIF | CYP4F2 146/4885CYP4A11 989/4885PKM 1053/4885 |
| US-20090203860-A1 | Nonpolar phase-soluble methathesis catalysts | MMAB, HMBS, PEAK1 | CYP4F2 272/4885CYP4A11 683/4885PKM 1039/4885 |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, PHOSPHO1 | CYP4F2 666/4885CYP4A11 2768/4885PKM 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.